alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Amendment to the Biopharmaceutical Services Agreement



 Exhibit 10.2 
 AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENT 
 THIS AMENDMENT
(“Amendment”) effective as of April 27, 2012 (“Effective Date”), is between Synageva BioPharma Corp., a Delaware corporation with a principal office at 128 Spring Street, Suite 520, Lexington MA 02421 (phone:
781-357-9900; fax: 781-357-9901) (“Synageva”) and Cytovance Biologics, Inc. a Delaware corporation having its principal place of business at 800 Research Parkway, Suite 200 Oklahoma City, OK 73104 (“Cytovance”). 

WHEREAS, Synageva and Cytovance are parties to a Sales and Services Agreement effective February 27, 2012 (the
“Agreement”); and 
 WHEREAS, the parties desire to modify the Agreement as described below. 

NOW, THEREFORE, in consideration of the above, with respect to the Agreement, the parties hereby agree to the following:

  

	 	1.	Capitalized terms used but not defined in this Amendment will have the meanings ascribed to them in the Agreement. 


 

	 	2.	The following new Section 33 is added: 

  

	 	33.	Disposition of Equipment 


Any and all additional capital requirements and associated equipment cost, including but not limited to: inspection, transportation,
qualifications, and validation cost will be the sole and exclusive economic responsibility of Synageva, so long as such associated equipment costs are limited to equipment that is used exclusively for performing the Services. All such costs are to
be paid for by Synageva in advance before Cytovance initiates purchases orders. 
 Any and all equipment purchased by Synageva
under this Agreement shall be and remain the sole property of Synageva, and is to be used by Cytovance solely for performing the Services. Upon request in writing from Synageva and at its sole cost, Cytovance shall make all reasonable U.S. Uniform
Commercial Code or other filings necessary to secure and evidence Synageva’s ownership of such equipment. Cytovance shall not remove such equipment from its facilities without the prior written consent of Synageva. Repairs and maintenance work
on such equipment shall only be carried out by authorized service providers. Cytovance is liable for damages to or loss of such equipment other than normal wear and tear. Cytovance shall, upon request from Synageva and at Synageva’s sole cost,
arrange to have the equipment shipped to a location designated by Synageva. 
 Upon execution, this Amendment shall be made a
part of the Agreement and shall be incorporated by reference. Except as provided herein, all other terms and conditions of the Agreement shall remain in full force and effect. 
 [The remainder of this page intentionally left blank.] 

  

					
		 		 	Page 1 of 2









 IN WITNESS WHEREOF, the parties hereto have executed or caused this Amendment to be
executed by their respective officers or other representatives duly authorized. 
  

							
	SYNAGEVA BIOPHARMA CORP.	    	CYTOVANCE BIOLOGICS, INC .
				
	By:	  	  
	    	By:	  	  

				
	Print Name:	  	Eugene J. Kim	    	Print Name:	  	  

				
	Title:	  	Legal Counsel, Director of Intellectual Property	    	Title:	  	  



  

					
		 		 	Page 2 of 2
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Antitrust Division

                    Notice is hereby given that, on May 18, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301*et seq.*                     (“the Act”), Southwest Research Institute—Cooperative Research Group on ROS-Industrial Consortium-Americas (“RIC-Americas”) has filed written notifications simultaneously with the Attorney General and the Federal Trade                           ( print page 35794)                        Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Imandra, Inc., Austin, TX; and Tormach, Inc., Madison, WI, have been added as parties to this venture.                

Also, Process Champ, LLC, Troy, MI, has withdrawn as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and RIC-Americas intends to file additional written notifications disclosing all changes in membership.

                    On April 30, 2014, RIC-Americas filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the                     **Federal Register**                     pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999).                

                    The last notification was filed with the Department on March 24, 2022. A notice was published in the                     **Federal Register**                     pursuant to Section 6(b) of the Act on May 12, 2022 (87 FR 29181).                

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2022-12599 Filed 6-10-22; 8:45 am]

BILLING CODE P
IV 

113TH CONGRESS 

2D SESSION H. CON. RES. 83 

Authorizing the use of Emancipation Hall in the Capitol Visitor Center 

for an event to celebrate the birthday of King Kamehameha I. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 11, 2014 

Ms. GABBARD (for herself and Ms. HANABUSA) submitted the following concurrent resolution; which was referred to the Committee on House Administration 

CONCURRENT RESOLUTION 

Authorizing the use of Emancipation Hall in the Capitol 

Visitor Center for an event to celebrate the birthday 

of King Kamehameha I. 

1 Resolved by the House of Representatives (the Senate 

2 concurring), 

3 SECTION 1. USE OF EMANCIPATION HALL FOR EVENT TO 

4 CELEBRATE BIRTHDAY OF KING KAMEHA5 MEHA I. 

6 (a) AUTHORIZATION.—Emancipation Hall in the 

7 Capitol Visitor Center is authorized to be used for an 

8 event on June 8, 2014, to celebrate the birthday of King 

9 Kamehameha I. 


smartinez on DSK6TPTVN1PROD with BILLS
2 

•HCON 83 IH 

1 (b) PREPARATIONS.—Physical preparations for the 

2 conduct of the ceremony described in subsection (a) shall 

3 be carried out in accordance with such conditions as may 

4 be prescribed by the Architect of the Capitol. 

Æ 


smartinez on DSK6TPTVN1PROD with BILLS
<TABLE> <S> <C>


<ARTICLE> 5
<MULTIPLIER> 1

<S>                           <C>
<PERIOD-TYPE>                 YEAR
<FISCAL-YEAR-END>             DEC-31-1996
<PERIOD-END>                  DEC-31-1996
<CASH>                          1,381,998
<SECURITIES>                            0
<RECEIVABLES>                   2,049,311
<ALLOWANCES>                            0
<INVENTORY>                       394,000
<CURRENT-ASSETS>                3,889,365
<PP&E>                            954,611
<DEPRECIATION>                    411,405
<TOTAL-ASSETS>                  7,390,160
<CURRENT-LIABILITIES>           2,585,562
<BONDS>                                 0
<PREFERRED-MANDATORY>                   0
<PREFERRED>                             0
<COMMON>                            4,262
<OTHER-SE>                     10,789,441
<TOTAL-LIABILITY-AND-EQUITY>    7,390,160
<SALES>                                 0
<TOTAL-REVENUES>                6,891,305
<CGS>                           6,949,037
<TOTAL-COSTS>                  10,584,099
<OTHER-EXPENSES>                        0
<LOSS-PROVISION>                        0
<INTEREST-EXPENSE>                      0
<INCOME-PRETAX>                (3,559,867)
<INCOME-TAX>                            0
<INCOME-CONTINUING>            (3,559,867)
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0
<CHANGES>                               0
<NET-INCOME>                   (3,559,867)
<EPS-PRIMARY>                        0.84
<EPS-DILUTED>                        0.84



</TABLE>
Neringa VENCKIENE, Petitioner v. UNITED STATES

No. 19-313

Supreme Court of the United States.

October 15, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Seventh Circuit denied.
<PAGE>



                         CHARDAN CHINA ACQUISITION CORP.




                                                     ______________, 2004

Chardan Ventures LLC
777 South Highway 101
Suite 215
Solana Beach, California 92075

Gentlemen:

     This letter will confirm our agreement that, commencing on the effective
date ("Effective Date") of the registration statement for the initial public
offering ("IPO") of the securities of Chardan China Acquisition Corp. ("SPAC")
and continuing until the consummation by SPAC of a "Business Combination" (as
described in SPAC's IPO prospectus), Chardan Ventures LLC shall make available
to SPAC certain office and secretarial services as may be required by SPAC from
time to time, situated at 777 South Highway 101, Suite 215, Solana Beach,
California 92075. In exchange therefore, SPAC shall pay Chardan Ventures LLC the
sum of $7,500 per month on the Effective Date and continuing monthly thereafter.

                                        Very truly yours,


                                        CHARDAN CHINA ACQUISITION CORP.




                                        By:
                                            -------------------------------
                                            Name:    Dr. Richard D. Propper
                                            Title:   Chairman of the Board

AGREED TO AND ACCEPTED BY:

CHARDAN VENTURES LLC


By:
   ---------------------------
   Name:
   Title:
Vincent ANZALONE, Petitioner, v. UNITED STATES.

No. 19-5396

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the United States Court of Appeals for the First Circuit denied.
United States Court of Appeals FOR THE EIGHTH CIRCUIT

_____________ No. 96-3787ND

_____________ United States of America, * * Appellee, * Appeal from the United States

* District Court for the District of v. * North Dakota. * Darryl Lawrence Thompson, * [UNPUBLISHED] * Appellant. *

_____________ Submitted: May 21, 1997

Filed: May 30, 1997

_____________ Before McMILLIAN, FAGG, and HANSEN, Circuit Judges.

_____________ PER CURIAM. Darry lLawrence Thompson appeals his guidelines sentence. Because th e controlling law is clear, an extended discus sion of the issue raised on appeal will serve no us eful purpose. Having reviewed the record and the parties' briefs, we rejec t Thompson's content

ion that the district court improperly refused to grant Thompson a two-l evel reduction for acceptance of responsibility. In our view, the district court' s findings are not clearly erroneous and no error of law appears. We thus affirm Thompson's sentence. See 8th Cir. R. 47B. A true copy. Attest: CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
IA 

113TH CONGRESS 

2D SESSION H. J. RES. 108 

Proposing an amendment to the Constitution of the United States to limit 

the number of terms that a Member of Congress may serve. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 4, 2014 

Mr. MULVANEY (for himself, Mr. SCALISE, Mr. RIBBLE, and Mr. PALAZZO) 

introduced the following joint resolution; which was referred to the Committee on the Judiciary 

JOINT RESOLUTION 

Proposing an amendment to the Constitution of the United 

States to limit the number of terms that a Member 

of Congress may serve. 

1 Resolved by the Senate and House of Representatives 

2 of the United States of America in Congress assembled

3 (two-thirds of each House concurring therein), That the fol4 lowing article is proposed as an amendment to the Con5 stitution of the United States, which shall be valid to all 

6 intents and purposes as part of the Constitution when 

7 ratified by the legislatures of three-fourths of the several 

8 States within seven years after the date of its submission 

9 for ratification: 


sroberts on DSK5SPTVN1PROD with BILLS
2 

•HJ 108 IH 

1 ‘‘ARTICLE — 

2 ‘‘SECTION 1. No person who has been a Senator for 

3 two terms shall again be eligible for election or appoint4 ment to the Senate. 

5 ‘‘SECTION 2. No person who has been a Representa6 tive for six terms shall again be eligible for election to the 

7 House of Representatives. 

8 ‘‘SECTION 3. For purposes of this article, any term 

9 a person serves as a Senator or Representative to fill a 

10 vacancy shall not be included in determining the number 

11 of terms that the person has been a Senator or Represent12 ative unless the period of time for which the person fills 

13 the vacancy is greater than three years in the case of a 

14 Senator or greater than one year in the case of a Rep15 resentative. 

16 ‘‘SECTION 4. For the purposes of this article, any 

17 term that began before the date of the ratification of this 

18 article shall not be included in determining the number 

19 of terms that a person has been a Senator or Representa20 tive.’’. 

Æ 


sroberts on DSK5SPTVN1PROD with BILLS
Amendment to Morgan Stanley 401(k) Savings Plan, dated as of February 28, 2012



 EXHIBIT 10.6 
 AMENDMENT TO 
 401(k) SAVINGS PLAN 

Morgan Stanley & Co. LLC (the “Company”) hereby amends the Morgan Stanley 401(k) Savings Plan (the “Plan”)
as follows: 
 1. Effective as of the consummation of the transactions described in the Purchase Agreement by and among SCI Services, Inc.,
Ocwen Financial Corporation and certain other parties dated as of October 19, 2011, Appendix A shall be amended (i) by adding the date of the consummation of the transactions described in the Saxon Purchase Agreement (as defined below) at
the end of the entry for SCI Services, Inc., Saxon Mortgage, Inc., Americas Moneyline, Inc., Saxon Mortgage Services, Inc. and Saxon Funding Management, Inc. in the list of Participating Companies contained therein indicating the cessation of such
entities’ participation in the Plan, and (ii) by adding the following new paragraph at the end of the Section headed “SCI Services, Inc., Saxon Mortgage, Inc., Americas Moneyline, Inc., Saxon Mortgage Services, Inc. and Saxon Funding
Management, Inc.”: 
 “Cessation of Participation of SCI Services, Inc., Saxon Mortgage, Inc., Americas Moneyline,
Inc., Saxon Mortgage Services, Inc. and Saxon Funding Management, Inc. Effective as of the consummation of the transactions described in the Purchase Agreement (the “Saxon Purchase Agreement”) by and among SCI Services, Inc., Ocwen
Financial Corporation and certain other parties dated as of October 19, 2011 (the “Saxon Closing Date”), (i) SCI Services, Inc., Saxon Mortgage, Inc., Americas Moneyline, Inc., Saxon Mortgage Services, Inc. and Saxon Funding
Management, Inc. and any subsidiaries (the “Saxon Companies”) shall cease to be Participating Companies in the Plan; (ii) employees of the Saxon Companies shall cease to actively participate in the Plan; and (iii) employees of
the Saxon Companies described as “Business Employees” in the Saxon Purchase Agreement immediately prior to the Saxon Closing Date shall become fully vested in all amounts allocated to their Accounts. Any such Business Employee shall be
treated as eligible to receive a Matching Contribution for 2012 pursuant to Section 6(k) of the Plan and such Matching Contribution shall be based on his or her 2012 Matched Contributions and Earnings prior to the Saxon Closing Date.”

 *  *  *  *  *  *  *  *  * 







 IN WITNESS WHEREOF, the Company has caused this Amendment to be executed
on its behalf as of this 28th day of February, 2012.

  

			
	MORGAN STANLEY & CO. LLC
		
	By:	 	 /s/ JEFF BRODSKY

	Title:	 	Global Head of Human Resources



  
 2
**Exhibit 31.2****CERTIFICATION**I, Jack R. Altherr, Jr., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Avondale Incorporated;  2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect to theperiod covered by this report;  3. Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periodspresented in this report;  4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, ismade known to us by others within those entities, particularly during the period inwhich this report is being prepared;  (b) Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by this reportbased on such evaluation; and  (c) Disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarterthat has materially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to the registrant’sauditors and the audit committee of the registrant’s board of directors (or personsperforming the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and report financialinformation; and  (b) Any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal control over financialreporting.        Date:  January 9, 2006 /s/ JACK R. ALTHERR, JR.   Jack R. Altherr, Jr.   Vice Chairman and Chief Financial Officer   
37
**EXHIBIT 32.2**

 

### **CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS REQUIRED BY**

# **SECTION906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Quarterly Report on Form 10-Qof Steinway Musical Instruments, Inc. (the “Company”) for the fiscal period endedSeptember 30, 2009 as filed with the Securities and Exchange Commission on thedate hereof (the “Report”), I, Dennis M. Hanson, Senior Executive VicePresident and Chief Financial Officer of the Company, certify that to the bestof my knowledge:

 

1. The Report fully complies with the requirements ofsection 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairlypresents, in all material respects, the financial condition and results ofoperations of the Company.

 

 
|             | /s/ Dennis M. Hanson                 |
|------------------|--------------------------------------|
|             |                                 |
|             | Senior Executive Vice  President and |
|             | Chief Financial Officer              |
|             | (Principal Financial  Officer)       |
|             |                                 |
| November 9, 2009 |                                 |

 

----
Thomas JAMES, Petitioner v. UNITED STATES

No. 19-5670

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
# C_2018064EN.01000101.xml

| 20.2.2018 | EN | Official Journal of the European Union | C 64/1 |
| --- | --- | --- | --- |

20.2.2018

EN

Official Journal of the European Union

C 64/1

---

Non-opposition to a notified concentration

(Case M.8804 — Bain Capital/Fedrigoni)

(Text with EEA relevance)

(2018/C 64/01)

On 15 February 2018, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

1

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M8804. EUR-Lex is the online access to European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M8804. EUR-Lex is the online access to European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---
Jesse MORENO, Petitioner, v. UNITED STATES.

No. 19-7974.

Supreme Court of the United States.

May 4, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.